Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,648 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00316433 | Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer | terminated | Phase 2 | 24 | Swedish Medical CenterOTHER | 1 | Apr 5, 2007 | clinicaltrials |
| NCT00425022 | VATS Lobectomy for Clinical Stage IB or II Lung Cancer | unknown | Phase 2 | 40 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 30, 2007 | clinicaltrials |
| NCT00061464 |
| Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy. |
| completed |
| Phase 2 |
| 48 |
| Eli Lilly and CompanyINDUSTRY |
| 1 |
| Jan 26, 2007 |
| clinicaltrials |
| NCT00190840 | A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 186 | Eli Lilly and CompanyINDUSTRY | 8 | Jan 26, 2007 | clinicaltrials |
| NCT00191230 | Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer | completed | Phase 2 | 70 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00191256 | Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer | completed | Phase 2 | 77 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00191490 | A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer | completed | Phase 2 | 162 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00191620 | Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer. | completed | Phase 2 | 64 | Eli Lilly and CompanyINDUSTRY | 4 | Jan 26, 2007 | clinicaltrials |
| NCT00260026 | Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer | completed | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00179686 | A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer | completed | Phase 2 | 40 | Celgene CorporationINDUSTRY | 1 | Dec 20, 2006 | clinicaltrials |
| NCT00407264 | Randomized Trial of Fluticasone in Bronchial Premalignancy | completed | Phase 2 | 90 | Amsterdam UMC, location VUmcOTHER | 1 | Dec 4, 2006 | clinicaltrials |
| NCT00168883 | Study for Patients With Non Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 80 | Charite University, Berlin, GermanyOTHER | 1 | Nov 1, 2006 | clinicaltrials |
| NCT00191841 | Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy | completed | Phase 2 | 50 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 24, 2006 | clinicaltrials |
| NCT00034606 | Comparing 3 Schedules of Alimta Plus Gemzar | completed | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Jul 19, 2006 | clinicaltrials |
| NCT00042679 | A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer. | completed | Phase 2 | — | Eli Lilly and CompanyINDUSTRY | 1 | Jul 19, 2006 | clinicaltrials |
| NCT00051493 | ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial. | completed | Phase 2 | 50 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 19, 2006 | clinicaltrials |
| NCT00339586 | First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene | unknown | Phase 2 | 40 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 21, 2006 | clinicaltrials |
| NCT00285675 | Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004 | unknown | Phase 2 | 25 | NovaceaINDUSTRY | 2 | May 31, 2006 | clinicaltrials |
| NCT00168922 | Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC) | unknown | Phase 2 | 50 | Charite University, Berlin, GermanyOTHER | 1 | Apr 27, 2006 | clinicaltrials |
| NCT00082472 | Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC) | unknown | Phase 1 / Phase 2 | 30 | ZivenaINDUSTRY | 1 | Apr 18, 2006 | clinicaltrials |
| NCT00168896 | A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage | unknown | Phase 2 / Phase 3 | 286 | Charite University, Berlin, GermanyOTHER | 1 | Feb 14, 2006 | clinicaltrials |
| NCT00150657 | Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer | unknown | Phase 2 | 45 | St. John Providence Health SystemOTHER | 1 | Nov 29, 2005 | clinicaltrials |
| NCT00254319 | Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | — | The Cooper Health SystemOTHER | 1 | Nov 16, 2005 | clinicaltrials |
| NCT00238849 | Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC. | unknown | Phase 2 | 40 | Integrated Community Oncology NetworkOTHER | 1 | Oct 14, 2005 | clinicaltrials |
| NCT00175747 | A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) | completed | Phase 2 / Phase 3 | 120 | University of British ColumbiaOTHER | 1 | Sep 15, 2005 | clinicaltrials |
| NCT00073385 | Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 225 | Titan PharmaceuticalsINDUSTRY | 3 | Aug 30, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Apr 5, 2007source: clinicaltrials